Sells molecular tests that assess disease risk and help healthcare providers choose treatments for patients across cancer care, prenatal screening and mental health.
10-K for FY2025, filed Feb 24, 2026Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We…View ↗
Our tests are generally designed to analyze genes and their expression levels to assess an individual’s risk for developing disease…View ↗
Oncology: Clarifying cancer risk and cancer treatment with genetic and genomic insights and companion diagnostic tests that are designed to…View ↗
Women's Health: Providing differentiated genetic insights and prenatal solutions for women of many ancestries, assessing cancer risk, and…View ↗
Mental Health: Leveraging pharmacogenomics to help clinicians understand how genetics may impact patient metabolism and response to…View ↗
Myriad earns money by processing molecular tests and billing customers when each test is completed and its results are released to a healthcare provider or patient.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
FY2025 revenue by product or service ↗$824.5M
10-K for FY2025, filed Feb 24, 2026
$824.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Hereditary Cancer
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
45%
FY2022: 45%
|
Hereditary Cancer, FY2025
$372.4M Sources
|
Sold outright |
|
Tumor Profiling
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
15%
FY2022: 19%
|
Tumor Profiling, FY2025
$121.7M Sources
|
Sold outright |
|
Prenatal
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
23%
FY2022: 17%
|
Prenatal, FY2025
$186.3M Sources
|
Sold outright |
|
Mental Health
Sold outright
10-K for FY2025, filed Feb 24, 2026 |
17% |
Mental Health, FY2025
$144.1M Sources
|
Sold outright |
Patients and healthcare providers use Myriad's tests. The company sells primarily through its sales force in the United States and Japan, while indirect channels and partnerships extend its reach in Europe and Asia-Pacific.
10-K for FY2025, filed Feb 24, 2026
10-K for FY2025, filed Feb 24, 2026
The Company has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented…View ↗
No. It lost $365.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$43.9MView ↗
8-K, filed Nov 4, 2026
Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid ExecutionView ↗
8-K, filed Oct 20, 2026
On October 19, 2026, Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Laboratory Corporation of America, a Delaware…View ↗
Growing. Revenue grew 19% in 4 years, from $690.6M in FY2021 to $824.5M in FY2025, about 5% a year.
EndoPredict sale
The older report described EndoPredict as a Myriad test; the latest says the business was divested to Eurobio, with Myriad retaining sales rights outside the European Union under license.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 24, 2026EndoPredict® Breast Cancer Prognostic Test: RNA expression test for assessing the aggressiveness of breast cancer. The EndoPredict test is…View ↗
EndoPredict® Breast Cancer Prognostic Test: RNA expression test for assessing the aggressiveness of breast cancer. The EndoPredict…View ↗
Cancer monitoring
The older report described Precise MRD as planned for research use only; the latest describes a tumor-informed test for monitoring tumor DNA through cancer care and surveillance.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 24, 2026Personalized genetic data, digital, and virtual consumer trends are converging to change traditional models of care. We believe significant…View ↗
Precise MRD™ Test: A tumor-informed test that can be used to monitor circulating tumor DNA (ctDNA) levels throughout a patient’s clinical…View ↗
Prenatal screening
FirstGene moved from a planned launch to limited early access: the latest report describes a single assay combining several prenatal testing methods.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Feb 24, 2026Personalized genetic data, digital, and virtual consumer trends are converging to change traditional models of care. We believe significant…View ↗
FirstGene® Multiple Prenatal Screen: a comprehensive prenatal genetic risk assessment test currently available through early access in a…View ↗
Competes with Natera, Foundation Medicine, Caris Life Sciences, Tempus, Laboratory Corporation of America, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth, NeoGenomics, BillionToOne, Fulgent Genetics, and Genomind
10-K for FY2025, filed Feb 24, 2026In oncology, we offer testing for patients across their cancer journey, from identification of genes that increase cancer risk, to…View ↗
Loading...